ABL Bio is a research-led biotechnology company, a pioneer in bispecific antibodies for immuno-oncology and neurodegenerative diseases. Delivering new approaches to address the highest unmet needs, we are committed to improving the lives of people all over the world. The company is pursuing a business model capable of mid-to-long-term growth through the technology transfer of various pipelines being developed based on its current core technology, the dual antibody platform 'Grabody™'. Based on the nature of the company's pipeline, market characteristics, and its technological capabilities, rapid technology transfer is anticipated.

Grabody-B is a core technology that enhances the permeability of the blood-brain barrier (BBB) and improves drug delivery to the brain, overcoming the limitations of standalone antibodies with its long half-life. It penetrates the BBB through a mechanism called RMT (Receptor Mediated Transcytosis) by utilizing the IGF1R shuttle target, which can recognize BBB receptors. IGF1R is highly expressed specifically in human brain microvascular (BMV) and neuron cells, minimizing off-target effects that could be caused by expression in other tissues. Currently, Grabody-B is recognized globally as a key technology that can overcome the limitations of standalone antibody-based therapies with low drug delivery rates to the brain due to BBB permeability issues. Grabody-T targets both tumor-expressed antigens and 4-1BB, activating immune cells to produce a powerful anticancer effect while resolving the liver toxicity issue associated with standalone 4-1BB antibodies. In monkey animal trials, no temporary or permanent liver toxicity was observed. All pipelines based on this platform activate T cells exclusively within the tumor microenvironment where TAA (Tumor Associated Antigen) expression is high, ensuring a high level of safety. Grabody-I is an immuno-oncology bispecific antibody platform with the ability to block two immune checkpoints. Existing PD-1 or PD-L1-based therapies suffer from low response rates and the development of resistance. Grabody-I has emerged as a promising new treatment alternative that can overcome these limitations by restoring the tumor-killing function of T cells, increasing the response rates of existing immune checkpoint inhibitors, and potentially leading patients to achieve remission.

Public

Biotech